Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695111 | 1.00 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL15243760 | 1.00 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL17282980 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL15228847 | 0.86 | CYP2D6 (0.53) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL15228846 | 0.86 | CYP2D6 (0.53) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL15228568 | 0.85 | CA2 (0.49) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL17282874 | 0.85 | CA2 (0.49) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL15228565 | 0.85 | CA2 (0.49) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL14515881 | 0.84 | CTSK (0.50) | CYP1A2CYP2C9CYP2C19HTTCA1 | |
| SCHEMBL14491979 | 0.84 | CTSK (0.50) | CYP1A2CYP2C9CYP2C19HTTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, BCL9 | CYP1A2 1207/4885CYP2C9 1097/4885CYP2C19 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.